CSBio CSBio

X
[{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine Announces Closing of Investment from Goldman Sachs Asset Management","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Norgine"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.

            Lead Product(s): Sodium Chloride,Sodium Bicarbonate,Potassium Chloride

            Therapeutic Area: Gastroenterology Product Name: Movicol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Goldman Sachs Asset Management

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing December 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.

            Lead Product(s): Potassium Chloride,Sodium Chloride,Ascorbic Acid

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Faes Farma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY